Sage Journals: Discover world-class research

Abstract

Background:

Whereas cellular immune function depends on energy supply and mitochondrial function, little is known on the impact of immunotherapies on cellular energy metabolism.

Objective:

The objective of this paper is to assess the effects of interferon-beta (IFN-β) on mitochondrial function of CD4⁺ T cells.

Methods:

Intracellular adenosine triphosphate (iATP) in phytohemagglutinin (PHA)-stimulated CD4⁺ cells of multiple sclerosis (MS) patients treated with IFN-β and controls were analyzed in a luciferase-based assay. Mitochondrial-transmembrane potential (ΔΨm) in IFN-β-treated peripheral blood mononuclear cells (PBMCs) was investigated by flow cytometry. Expression of genes involved in mitochondrial oxidative phosphorylation (OXPHOS) in CD4⁺ cells of IFN-β-treated individuals and correlations between genetic variants in the key metabolism regulator PGC-1α and IFN-β response in MS were analyzed.

Results:

IFN-β-treated MS patients exhibited a dose-dependent reduction of iATP levels in CD4⁺ T cells compared to controls (p < 0.001). Mitochondrial effects were reflected by depolarization of ΔΨm. Expression data revealed changes in the transcription of OXPHOS-genes. iATP levels in IFN-β-responders were reduced compared to non-responders (p < 0.05), and the major T allele of the SNP rs7665116 of PGC-1α correlated with iATP-levels.

Conclusion:

Reduced iATP-synthesis ex vivo and differential expression of OXPHOS-genes in CD4⁺ T cells point to unknown IFN-β effects on mitochondrial energy metabolism, adding to potential pleiotropic mechanisms of action.

Keywords

Multiple sclerosis disease-modifying therapy (DMT)interferon-β immune cellular energy metabolism oxidative phosphorylation

Get full access to this article

View all access options for this article.

References

Calabrese

Bernardi

Atzori

. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis. Mult Scler 2012; 18: 418–424.

Schwid

Panitch

. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007; 29: 2031–2048.

Alexander

Harris

Wells

. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010; 16: 801–809.

Kvarnström

Ydrefors

Ekerfelt

. Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13. J Neurol Sci 2013; 325: 79–85.

Croze

Yamaguchi

Knappertz

. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 2013; 13: 443–451.

Brendecke

Prinz

. How type I interferons shape myeloid cell function in CNS autoimmunity. J Leukoc Biol 2012; 92: 479–488.

Fox

Hammerman

Thompson

. Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol 2005; 5: 844–852.

Haghikia

Hohlfeld

Gold

. Therapies for multiple sclerosis: Translational achievements and outstanding needs. Trends Mol Med 2013; 19: 309–319.

Puigserver

Andersson

. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115–124.

10.

Haghikia

Perrech

Pula

. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PloS One 2011; 6: e18506.

11.

Che

Metzger

Portal

. Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease. Mol Neurodegener 2011; 6: 1.

12.

Weydt

Soyal

Gellera

. The gene coding for PGC-1alpha modifies age at onset in Huntington’s Disease. Mol Neurodegener 2009; 4: 3.

13.

Taherzadeh-Fard

Saft

Andrich

. PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009; 4: 10.

14.

Arning

Haghikia

Taherzadeh-Fard

. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) 2010; 88: 431–436.

15.

Falchi

Isola

Diana

. Characterization of depolarization and repolarization phases of mitochondrial membrane potential fluctuations induced by tetramethylrhodamine methyl ester photoactivation. FEBS J 2005; 272: 1649–1659.

16.

Chan

Seguin

Magnus

. Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: Termination of CNS autoimmune inflammation and modulation by interferon-beta. Glia 2003; 43: 231–242.

17.

Fernald

Knott

Pachner

. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 2007; 178: 5076–5085.

18.

Byun

Caillier

Montalban

. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337–344.

19.

Sottong

Rosebrock

Britz

. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 2000; 7: 307–311.

20.

Nickel

Bestard

Volk

. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant 2009; 14: 426–431.

21.

Galligan

Pennell

Murooka

. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult Scler 2010; 16: 1458–1473.

22.

Skrzipek

Vogelgesang

Bröker

. Differential effects of interferon-β1b on cytokine patterns of CD4⁺ and CD8⁺ T cells derived from RRMS and PPMS patients. Mult Scler 2012; 18: 674–678.

23.

Kovarik

Sauer

Schaljo

. Molecular mechanisms of the anti-inflammatory functions of interferons. Immunobiology 2007; 212: 895–901.

24.

Prinz

Kalinke

. New lessons about old molecules: How type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol Med 2010; 16: 379–386.

25.

Weinstock-Guttman

Badgett

Patrick

. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171: 2694–2702.

26.

Killestein

Polman

. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011; 7: 221–228.

27.

Vega

Huss

Kelly

. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000; 20: 1868–1876.

28.

Puigserver

Rhee

Donovan

. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550–555.

29.

Witte

Nijland

Drexhage

JAR

. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013; 125: 231–243.

30.

St-Pierre

Drori

Uldry

. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006; 127: 397–408.

31.

Weydt

Soyal

Landwehrmeyer

. A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurol 2014; 14: 1.

32.

Eschbach

Schwalenstöcker

Soyal

. PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 2013; 22: 3477–3484.

33.

Polman

Bertolotto

Deisenhammer

. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740–750.

34.

Durelli

Barbero

Bergui

. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 646–651.

35.

Pappas

Coppola

Gabatto

. Longitudinal system-based analysis of transcriptional responses to type I interferons. Physiol Genomics 2009; 38: 362–371.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.21 MB

Interferon-beta affects mitochondrial activity in CD4 + lymphocytes: Implications for mechanism of action in multiple sclerosis

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material